Recombinant Human JAK2 Protein, DYKDDDDK-tagged
Cat.No. : | JAK2-151H |
Product Overview : | Recombinant Human Janus kinase 2(JAK2)(NM_004972) protein, with a DYKDDDDK tag, was expressed in human cells. |
- Specification
- Gene Information
- Related Products
Description : | This gene product is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. It has been found to be constituitively associated with the prolactin receptor and is required for responses to gamma interferon. Mice that do not express an active protein for this gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis. |
Source : | Human cells |
Species : | Human |
Tag : | DYKDDDDK |
Form : | Purified protein formulated in a sterile solution of TBS buffer, pH7.37, without any preservatives. |
Molecular Mass : | 130.5 kDa |
Endotoxin : | Endotoxin level is < 0.1 ng/µg of protein (<1EU /µg) |
Purity : | >90% by SDS-PAGE gel and Coomassie Blue staining |
Applications : | Antigens, Western, ELISA and other in vitro binding or in vivo functional assays, and protein-protein interaction studies. |
Gene Name : | JAK2 Janus kinase 2 [ Homo sapiens ] |
Official Symbol : | JAK2 |
Synonyms : | JAK2; Janus kinase 2; tyrosine-protein kinase JAK2; JTK10; JAK-2; Janus kinase 2 (a protein tyrosine kinase); THCYT3; |
Gene ID : | 3717 |
mRNA Refseq : | NM_004972 |
Protein Refseq : | NP_004963 |
MIM : | 147796 |
UniProt ID : | O60674 |
Products Types
◆ Recombinant Protein | ||
JAK2-2477H | Recombinant Human JAK2 protein(841-1130 aa), C-His-tagged | +Inquiry |
JAK2-35H | Recombinant Human JAK2 and EPOR Fusion Protein, FLAG/His-tagged | +Inquiry |
JAK2-5439H | Recombinant Human Janus Kinase 2, GST-tagged | +Inquiry |
JAK2-33H | Recombinant Human JAK2 (JH2 Domain) (W659A, W777A,F794H) Protein, His-tagged | +Inquiry |
Jak2-3627M | Recombinant Mouse Jak2 Protein, Myc/DDK-tagged | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (7)
Ask a questionJAK2 mutations, particularly JAK2 V617F, are hallmarks of several MPNs, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. These mutations lead to uncontrolled cell proliferation.
Upon cytokine binding to its receptor, JAK2 becomes activated through phosphorylation. This activation leads to the phosphorylation and activation of STAT (Signal Transducers and Activators of Transcription) proteins, which then translocate to the nucleus and regulate gene expression.
JAK2 is a non-receptor tyrosine kinase that plays a pivotal role in cytokine signaling, mediating cellular responses to growth factors and various cytokines.
JAK2 is crucial for hematopoiesis, especially in the signaling pathways of erythropoietin and thrombopoietin, which are essential for red blood cell and platelet production, respectively.
JAK2 associates with the intracellular domains of specific cytokine receptors. Upon cytokine binding, JAK2 becomes activated, leading to downstream signaling events. This interaction is vital for mediating cellular responses to various cytokines.
Yes, there are several JAK2 inhibitors, such as ruxolitinib and fedratinib, which are used to treat MPNs. They work by inhibiting the kinase activity of JAK2, thereby reducing aberrant cell proliferation.
Yes, one of the most well-known mutations is JAK2 V617F, which results in constitutive activation of the kinase. This mutation is associated with various myeloproliferative neoplasms (MPNs).
Customer Reviews (3)
Write a reviewQuick response from customer service.
Product performed as expected.
Satisfied with product quality.
Ask a Question for All JAK2 Products
Required fields are marked with *
My Review for All JAK2 Products
Required fields are marked with *
Inquiry Basket